.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Baxter
Dow
Citi
Moodys
UBS
Argus Health
McKesson
Express Scripts
Novartis

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,431,943

« Back to Dashboard

Which drugs does patent 7,431,943 protect, and when does it expire?


Patent 7,431,943 protects UCERIS and is included in one NDA. There has been one Paragraph IV challenge on Uceris.

This patent has twenty-four patent family members in seventeen countries.

Summary for Patent: 7,431,943

Title:Controlled release and taste masking oral pharmaceutical compositions
Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
Inventor(s): Villa; Roberto (Panama City, PA), Pedrani; Massimo (Panama City, PA), Fossati; Mauro Ajani (Panama City, PA), Fossati; Lorenzo (Panama City, PA)
Assignee: Cosmo Technologies Limited (Wicklow, IE)
Application Number:10/009,532
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Valeant Pharms Intl
UCERIS
budesonide
TABLET, EXTENDED RELEASE;ORAL203634-001Jan 14, 2013RXYesYes7,431,943► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,431,943

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI99A1317Jun 14, 1999
ItalyMI00A0422Mar 03, 2000
PCT Information
PCT FiledJune 09, 2000PCT Application Number:PCT/EP00/05356
PCT Publication Date:December 21, 2000PCT Publication Number: WO00/76478

Non-Orange Book Patents for Patent: 7,431,943

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,293,273Controlled release and taste masking oral pharmaceutical composition► Subscribe
9,592,203Controlled release and taste masking oral pharmaceutical composition► Subscribe
8,895,064Controlled release and taste masking oral pharmaceutical composition► Subscribe
7,410,651Controlled release and taste masking oral pharmaceutical composition► Subscribe
8,029,823Controlled release and taste masking oral pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,431,943

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey200200562► Subscribe
Russian Federation2246293► Subscribe
Portugal1183014► Subscribe
Norway331642► Subscribe
Norway20016108► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Moodys
Merck
Harvard Business School
Teva
QuintilesIMS
Baxter
Daiichi Sankyo
Julphar
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot